Lansoprazole (Form-I)
Mechanism of Action
Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity.Indication
PREVACID and PREVACID SoluTab are proton pump inhibitors (PPIs) indicated for the:1. Treatment of active duodenal ulcer in adults.
2. Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults.
3. Maintenance of healed duodenal ulcers in adults.
4. Treatment of active benign gastric ulcer in adults.
5. Healing of non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults.
6. Risk reduction of NSAID-associated gastric ulcer in adults.
7. Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.
8. Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older.
9. Maintenance of healing of EE in adults.
10. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults.
Dr. Reddy's的专长
Dr. Reddy's总部位于印度海得拉巴，是全球领先的活性药物成分（API）供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。
Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API（如类固醇，多肽，复杂长链分子和高效API（HPAPI /肿瘤药物））方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准，从而为这一专业知识提供补充。 Dr. Reddy's博士 Lansoprazole (Form-I) API是研发，知识产权和监管方面广泛专业知识的结果。
帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量，安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化，从而避免短缺并满足需求的突然激增。
联系我们
请填写以下表格，我们会尽快与您联系
免责声明
受有效专利保护的产品不得在销售此类产品构成专利侵权的国家/地区销售。可获得性可能仅限于某些市场或国家/地区。有关可获得性和产品适用性的更多信息，请 我们联系 .
所有产品信息，包括有关活性药物成分（API）、适应症和可能的作用机制的信息均基于公开的产品标签。
给我们发电子邮件:
api@drreddys.com
|
+91 40 49002253